Global HIV Infection Pipeline Analysis
Upcoming SlideShare
Loading in...5
×
 

Global HIV Infection Pipeline Analysis

on

  • 116 views

“Global HIV Infection Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drugs being developed for the treatment of HIV Infection. Research report covers all the ongoing ...

“Global HIV Infection Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drugs being developed for the treatment of HIV Infection. Research report covers all the ongoing drugs being developed in various clinical development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the HIV Infection drug market based upon development process.

For Report Sample Contact: rajesh@pnspharma.com

Statistics

Views

Total Views
116
Views on SlideShare
116
Embed Views
0

Actions

Likes
0
Downloads
0
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Global HIV Infection Pipeline Analysis Global HIV Infection Pipeline Analysis Document Transcript

  • Global HIV Infection Pipeline Analysis The discovery of HIV virus, which causes AIDS, dates back to more than 30 years. Currently, there are more than 30 drugs in the market which have been approved by the FDA for the treatment of HIV infection. Consequent to the introduction of retrovirals in 1996, HIV is not considered to be a death sentence anymore. The advancements in this field have led to new drugs being produced which have been successful in improving the quality of life for HIV patients and prevented the virus from developing into AIDS. The rate of HIV infection and the number of deaths due to AIDS has been on a declining note at a positive rate across the globe. It has been estimated that the death rate reduced from 2.3 million in 2005 to 1.6 in 2012, with the rates for children being even much lower. A major cause for such drastic changes in the infection rates has been the improved access to antiretroviral drugs and therapy in recent years. “Global HIV Infection Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drugs being developed for the treatment of HIV Infection. Research report covers all the ongoing drugs being developed in various clinical development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the HIV Infection drug market based upon development process. For Report Sample Contact: rajesh@pnspharma.com Following parameters for each drug profile in clinical development phase are covered in “Global HIV Infection Pipeline Analysis” research report: • Drug Profile Overview • Alternate Names for Drug • Active Indication • Phase of Development • Mechanism of Action • Brand Name • Patent Information • Orphan Designation by Indication, Country & Organisation • Country for Clinical Trial
  • • Owner / Originator/ Licensee/Collaborator • Administrative Route • Drug Class • ATC Codes HIV Infection Drug Development by Clinical Phase: • Research: 31 • Preclinical: 140 • Phase-I: 53 • Phase-I/II: 18 • Phase-II: 39 • Phase-III: 7 • Preregistration: 2 • Registered: 2 • Marketed: 34 For Report Sample Contact: rajesh@pnspharma.com Each Drug Profile has Tables Representing Following Information: • Alternate Names • Originator & Owner • Collaborator • Technology Provider • Licensee • Highest Development Phase • Indications • Class • Mechanism of Action • ATC code • Designated Brand Name & Orphan Designation